Clinical Trials · NCT02366208
Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Enrollment
- 116
- Start date
- May 2011
- Locations
- 12 sites, China
- Primary endpoint
- loss of HBeAg